Medical

methoxsalen

Also found in: Wikipedia.

methoxsalen

 [mĕ-thok´sah-len]
an acrylic acid compound that induces melanin production on exposure of the skin to ultraviolet radiation; used orally and topically in the treatment of idiopathic vitiligo, mycosis fungoides, and psoriasis.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

methoxsalen

A photosensitising psoralen that is given systemically or topically before the skin is exposed to UV light, as part of treatment for psoriasis, eczema, vitiligo and some cases of cutaneous lymphoma.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

methoxsalen

Oxsoralen® Dermatology A photosensitizing psoralen, given systemically or topically, after which the skin is exposed to UV light. See Psoriasis, PUVA.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
Mentioned in
References in periodicals archive
Lange, "Outcomes of pregnancies among women and partners of men with a history of exposure to methoxsalen photochemotherapy (PUVA) for the treatment of psoriasis," JAMA Dermatology, vol.
Impetigo Herpetiformis: Review of Pathogenesis, Complication, and Treatment
Topical methoxsalen photochemotherapy in the treatment of palmoplantar pustulosis and psoriasis.
A comparative study of efficacy of hand foot psoralen-ultraviolet a therapy versus sequential therapy of topical clobetasol propionate with topical calcipotriol ointment in palmoplantar psoriasis
Pathak, "Part IV: basic considerations of the psoralens: historical aspects of methoxsalen and other furocoumarins 11 from the Division of Dermatology, University of Oregon Medical School, Portland, Oregon," Journal of Investigative Dermatology, vol.
Differential Effects of Angelicin Analogues on NF-[kappa]B Activity and IL-8 Gene Expression in Cystic Fibrosis IB3-1 Cells
Cases Sex Age Why the treatment (year-old) of PUVA was given 1(2) Female 45 Vitiligo 2(3) Male 50 Psoriasis 3(4) Male 80 Psoriasis 4(5) Female 57 Mycosis fungoides 5(6) Female 65 Psoriasis 6(7) Female 67 Psoriasis 7(8) Male 58 Psoriasis 8(9) Male 61 Psoriasis 9 (present Female 26 Mycosis fungoides case) Cases Type of UVA 1(2) Topical PUVASOL 2(3) Oral PUVA (methoxsalen) 3(4) Oral PUVA (5-MOP) 4(5) Oral PUVA (8-MOP) 5(6) Oral PUVA (8-MOP) 6(7) UVA 7(8) PUVA (unspecified) 8(9) Oral PUVA (oxsoralen) 9 (present Oral PUVA (8-MOP) case)
PUVA Induced Bullous Pemphigoid in a Patient with Mycosis Fungoides
Components Amount (%) S- ASR ASR 1 Butylphthalide 4.35 2.47 2 Pentadecane, 8-heptyl- 0.29 -- 3 Z-Butylidenephthalide 8.79 4.61 4 b-Eudesmol 0.13 -- 5 E-Butylidenephthalide 0.15 0.11 6 Senkyunolide A 3.14 2.43 7 Muurola-4,11-diene 0.14 0.08 8 Z-Ligustilide 49.8 41.5 9 1-Nonadecene 0.56 0.36 10 Cryptone 0.58 0.31 11 3,9-Diethyl-6-tridecanol 0.21 0.14 12 5-(2-Thienyl)-4-pyrimidinamine 0.19 0.13 13 g-Eudesmol 0.27 0.10 14 E-Ligustilide 8.30 4.55 15 6,7-Dihydroxyligustilide 0.12 0.09 16 Senkyunolide F 0.18 0.10 17 Hexadecanoic acid 0.01 -- 18 Senkyunolide H 0.12 0.04 19 Senkyunolide I 0.38 0.13 20 1-Octadecanol 0.20 -- 21 Methoxsalen 0.22 0.12 22 Marmesin 0.21 -- 23 Lomatin 0.70 0.53 (a) RRI: Related retention indices calculated against n-alkanes.
The sulfur-fumigation reduces chemical composition and biological properties of Angelicae sinensis radix
Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation.
Molecular Pathology of Skin Neoplasms of the Head and Neck
Treatment of vitiligo with oral methoxsalen and UVA.
Guidelines for the management of vitiligo
Comparison of trioxsalen bath and oral methoxsalen PUVA in psoriasis.
EFFECTIVENESS AND SAFETY OF NARROW BAND ULTRAVIOLET B THERAPY IN CHRONIC PLAQUE PSORIASIS
(21.) PUVA treatment in lichen planus: comparison of oral and external methoxsalen regimens.
Lichen Planus with extensive cutaneous and oral manifestations--a case report and review of literature
M2 EQUITYBITES-February 16, 2012-Valeant Pharmaceuticals International Inc awarded FDA approval of additional manufacturer of methoxsalen for psoriasis(C)2012 M2 COMMUNICATIONS http://www.m2.com
Valeant Pharmaceuticals International Inc awarded FDA approval of additional manufacturer of methoxsalen for psoriasis
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.